Vaccinex Provides Update on ActivMAb® Platform: Multiple Project Deals and Presentation at SITC

Core Insights - Vaccinex, Inc. has signed multiple proprietary project agreements with major pharmaceutical companies, leveraging its ActivMAb® technology for antibody discovery [1][2] - The ActivMAb® platform is designed to express complex proteins, enabling the development of various antibody-based therapies targeting difficult membrane proteins [2][4] - The company is actively presenting its research at the Society for Immunotherapy of Cancer's 29th Annual Meeting, showcasing successful antibody discovery campaigns [2][3] Company Overview - Vaccinex is focused on treating neurodegenerative diseases and cancer through the inhibition of semaphorin 4D (SEMA4D), with its lead drug candidate, pepinemab, currently in clinical trials [5][6] - Pepinemab is being evaluated in combination with KEYTRUDA® and BAVENCIO® for various cancer indications, including recurrent head and neck cancer and metastatic pancreatic adenocarcinoma [5][6] - The company holds global commercial and development rights to pepinemab and collaborates with Merck Sharp & Dohme Corp. for the KEYNOTE-B84 study [6] Technology and Innovation - The ActivMAb® technology allows for the discovery of antibodies specific to complex membrane antigens, which are often challenging for traditional drug development [2][4] - The platform has already led to the identification of a clinical candidate, CHS-114, which is in development for cancer immunotherapy [4] - Vaccinex's technology is positioned to address high-value targets that have shown low efficacy or high toxicity with small molecule drugs [4]